View of Dual anti-human epidermal growth factor receptortype 2 blockade with taxane as first-line treatment for HER2-positive breast cancer with visceral metastases: a technology incorporation assessment within the Brazilian Unified Health System

Return to Article Details Dual anti-human epidermal growth factor receptortype 2 blockade with taxane as first-line treatment for HER2-positive breast cancer with visceral metastases: a technology incorporation assessment within the Brazilian Unified Health System Download Download PDF